Study identifier:NIS-RCN-SYM-2012/1
ClinicalTrials.gov identifier:NCT01785901
EudraCT identifier:N/A
CTIS identifier:N/A
The asthma control rate achieved by budesonide/formoterol in clinical practice in China
asthma
-
No
-
All
1502
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Aug 2016 by AstraZeneca
AstraZeneca
-
This is a multi-centre, cross-sectional study planned to be conducted in China. The study aims to observe about 1500 asthma patients who have already received budesonide/formoterol combination treatment by physicians' determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China.
The asthma control rate achieved by budesonide/formoterol in clinical practice in China.
Location
Location
Beijing, Beijing, China
Location
Harbin, Heilongjiang, China
Location
Hangzhou, Zhejiang, China
Location
Guangzhou, Guangdong, China
Location
Nanjing, Jiangsu, China
Location
Chengdu, Sichuan, China
Location
Qingdao, Shandong, China
Location
Wenzhou, Zhejiang, China
Arms | Assigned Interventions |
---|---|
Target subject population 1500 Asthma patients who have already received the treatment of budesonide/formoterol by physicians’ determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China | Other: without interventions without interventions Other Name: without interventions |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.